Reports
SGLT2 Inhibitors Market Insights, Size, Share & Industry Report, 2026-2034
REPORT DETAILS
REPORT DETAILS
ABOUT THIS REPORT
Market Statistics
Market Overview
The global SGLT2 inhibitors market size was valued at USD 18.32 billion in 2025. According to our SGLT2 inhibitors market forecast, the market is projected to account for a CAGR of 6.9% between 2026 and 2034. The market growth is primarily driven by the global rise of the aging population and increasing new drug approvals.
Key Insights
- North America led the market with a 37.32% revenue share in 2025. The rising prevalence of diabetes has led to increased demand for SGLT2 inhibitors in the region.
- Asia Pacific is projected to witness a CAGR of 7.5% during the forecast period. The growing aging population has led to a rising incidence of type 2 diabetes in the region.
- The type 2 diabetes segment accounted for a market revenue share of 88.5% in 2025. The growing prevalence of obesity has resulted in a surge in type 2 diabetes cases.
- The online pharmacies segment is projected to witness the fastest growth, at a 7.9% CAGR. Online pharmacies offer unparalleled convenience to patients, especially those residing in remote or underserved areas.
Market Statistics
- 2025 Market Size: USD 18.32 billion
- 2034 Projected Market Size: USD 33.51 billion
- CAGR (2026–2034): 6.9%
- North America: Largest Market in 2025
Industry Dynamics
- The rising geriatric population globally has resulted in an increased incidence of diabetes and other related health conditions. This has resulted in a greater need for SGLT2 inhibitors.
- Clinical guidelines and recommendations supporting the use of SGLT2 inhibitors for specific patient groups are contributing to the market expansion.
- The growing focus on the development of fixed-dose combination drugs is expected to create several market opportunities.
- The high cost of medication may present market challenges.
To Understand More About this Research: Download Sample Report
The sodium-glucose co-transporter 2 (SGLT2) inhibitors market encompasses medications primarily used to manage type 2 diabetes mellitus (T2DM). They work by inhibiting the SGLT2 proteins in the kidneys, which are responsible for reabsorbing glucose back into the bloodstream. SGLT2 inhibitors function by reducing the renal threshold for glucose, leading to increased urinary glucose excretion. This SGLT2 inhibitors mechanism of action not only lowers blood glucose but also induces osmotic diuresis, which leads to weight loss and reduced blood pressure.
The market is growing beyond its traditional role in diabetes care. SGLT2 inhibitors are increasingly being used for treating other conditions such as heart and kidney diseases. The use of these inhibitors is growing in the treatment of chronic kidney disease (CKD) and heart failure. Recent updates from the American Diabetes Association (ADA) have further contributed to the SGLT2 inhibitors market trends of increased use. The ADA recommends these inhibitors for patients with non-dialysis-dependent CKD to slow down the disease’s progression and help with heart health. This has further strengthened its long-term clinical relevance.
The increasing diabetes prevalence is expected to continue to support the long-term demand for the treatment. According to the International Diabetes Federation, the number of adults living with diabetes between the ages of 20 and 79 was approximately 589 million in 2024. This is projected to rise to 853 million by the year 2050. The increasing patient pool, along with the improvement in the diagnosis and treatment of the disease at a relatively early stage, is expected to boost the SGLT2 inhibitors market growth. As a result, demand for these drugs is expected to remain strong in the coming years.
Supportive SGLT2 inhibitors clinical guidelines and recommendations from organizations such as the ADA and the European Association for the Study of Diabetes (EASD) have also helped to drive market momentum. Their increasing endorsement of SGLT2 inhibitors for selected patients with diabetes, CKD, and cardiovascular risk profiles has improved prescriber confidence and extended the relevance of SGLT2 therapy beyond glucose control. At the same time, lifecycle management strategies, label extensions, and the introduction of fixed-dose combination products are helping manufacturers expand their market share of SGLT2 inhibitors.
Market Drivers and Trends
Global Rise of Aging Population
The increasing population of geriatric patients worldwide has led to a higher incidence of diabetes and other related metabolic disorders. Elderly populations are at a higher risk of developing type 2 diabetes, CKD, and cardiovascular complications. Hence, there is a need for effective oral drugs, such as SGLT2 inhibitors, in the type 2 diabetes treatment market.
The global population of people aged 65 years or older is estimated to increase from 761 million in 2021 to 1.6 billion in 2050, according to data from the United Nations. As the population of older adults increases, so does the prevalence of age-related conditions such as metabolic and renal diseases. This supports long-term demand for therapies targeting glycemia and cardiorenal outcomes in the geriatric diabetes market.
Rising New Drug Approvals
The SGLT2 inhibitors market trends reveal that the sector is also driven by regulatory clearances and product label expansions across key markets. SGLT2 inhibitors are no longer perceived simply as antidiabetics. They are increasingly positioned for use beyond diabetology into cardiovascular and nephrology care.
The FDA approved bexagliflozin for adults with type 2 diabetes in January 2023. This bexagliflozin approval provided a new oral treatment option for the drug class. In September 2023, the FDA approved Jardiance (empagliflozin) for adults with chronic kidney disease. It made SGLT2 inhibitors relevant for nephrology-based patient care. In June 2024, Farxiga (dapagliflozin) received approval from the FDA for the improvement of glycemic control in pediatric patients aged 10 years and older with type 2 diabetes. The dapagliflozin pediatric approval has widened the addressable patient base and created new SGLT2 inhibitors market opportunities.
Such developments are commercially important as they expand the class to new patient populations, reinforce physician familiarity, and expand the geographic reach of where these therapies are prescribed. As the treatment paradigms continue to evolve, the prescription demand for SGLT2 inhibitors is expected to come not only from endocrinologists but also from nephrologists, cardiologists, primary care physicians, and specialists in hospitals.
Expanding Use in Cardiorenal Care
One of the most notable trends in the SGLT2 inhibitors market is the move towards cardiorenal use. In comparison to past market narratives, which were dominated by glucose control alone, the current demand for SGLT2 inhibitors is increasingly driven by their role in managing CKD and heart failure. As such, this is helping to create a diversified revenue portfolio, which could eventually alleviate overdependence on type 2 diabetes alone.
Growth of Fixed-Dose Combinations and Therapy Optimization
Pharmaceutical manufacturers are also looking for growth opportunities through FDCs as well as local product launches. Combination products, such as SGLT2 inhibitors combined with other antidiabetic drugs, have growth potential for patient compliance. SGLT2 inhibitor combination drugs can simplify drug regimens as well as differentiate brands in the SGLT2 inhibitors competitive landscape. The trend is particularly relevant for high-volume, price-sensitive markets for diabetes therapies. It’s because convenience and affordability influence prescribing behavior in these markets.
Segment Insights
SGLT2 Inhibitors Market Breakdown by Indication
The global SGLT2 inhibitors market segmentation, based on indication, includes cardiovascular, chronic kidney disease (CKD), type 2 diabetes, and others. In 2025, the type 2 diabetes segment accounted for the largest market share of 88.5%. The increasing incidence of obesity due to unhealthy dietary habits, a lack of physical activity, and the consumption of high-calorie foods is one of the major reasons for the surge in type 2 diabetes cases. Physical inactivity is a significant risk factor for the development of type 2 diabetes. People living in modern societies experience a high level of physical inactivity due to physically inactive occupations, increased time spent watching screens, and a lack of physical exertion. A diet consisting of unhealthy foods is another risk factor for the development of type 2 diabetes. Since type 2 diabetes is more prevalent compared to type 1 diabetes, the treatment population for type 2 diabetes is high, which is one of the key contributors to the leading position of the type 2 diabetes SGLT2 inhibitors market.
Although type 2 diabetes currently leads, the CKD and cardiovascular segments are becoming increasingly important from a strategic growth perspective. Increased awareness of renal and cardiovascular benefits is expanding the class’s role in disease management and enhancing the value proposition in patients with multiple chronic conditions. According to the SGLT2 inhibitors market outlook, this is likely to drive a more diversified indication mix going forward.
SGLT2 Inhibitors Market by Drug Insights
Based on drug, the market includes Farxiga (dapagliflozin), Jardiance (empagliflozin), Invokana (canagliflozin), Inpefa (sotagliflozin), Qtern (dapagliflozin/saxagliptin), and other SGLT2 inhibitors. Of these, Jardiance and Farxiga are particularly notable for their strong brands, broad clinical visibility, and growing use in the diabetes and cardiorenal areas. Medications with greater label depth and familiarity among physicians will likely be better positioned to maintain sales in developed markets. Meanwhile, the recently launched products and fixed-dose combinations could potentially provide opportunities for future growth in particular markets.
SGLT2 Inhibitors Market by Distribution Channel Insights
The global SGLT2 inhibitors market segmentation, based on distribution channel, includes hospital pharmacies, online pharmacies, and retail pharmacies. The online pharmacies segment is expected to witness the fastest growth, at a 7.9% CAGR. The online pharmacies give patients unparalleled convenience, particularly for patients who live in remote or hard-to-reach places. The expanded access to online pharmacies has led to an increase in the market penetration of SGLT2 inhibitors. Moreover, online pharmacies offer patients competitive prices or discounts on medications they need to take for an extended period, such as SGLT2 inhibitors. The global acceptance of e-commerce and digital health platforms has normalized online pharmacies for healthcare needs. As such, patients have gained trust in online pharmacies.
Hospital and retail pharmacies will likely continue to play a significant role, especially in markets where specialist prescribing, reimbursement approval, and face-to-face counseling are significant drivers for therapy initiation. However, online channels are emerging as a growing area, as chronic disease patients increasingly value accessibility, support, and home delivery for maintenance therapy. Online channels are also benefiting from digital health pharmacy adoption.
Regional Insights
The study offers SGLT2 inhibitors market share by region insights of North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America
The North America SGLT2 inhibitors market led the global market with a 37.32% revenue share in 2025. The region benefits from a high diagnosed prevalence of diabetes, increased obesity burden, early uptake of innovative branded therapies, and better access to specialist care and reimbursement systems. These factors support the overall adoption of SGLT2 inhibitors across different diabetes and cardiorenal treatment settings.
The prevalence of diabetes in the U.S. remains high. This continues to sustain the market for advanced oral antidiabetic agents in the U.S. diabetes drug market. The region also benefits from a strong level of disease awareness, screening activity, and established prescribing pathways for branded medicines.
Europe
The Europe SGLT2 inhibitors market is a significant market in the global SGLT2 inhibitors sector. The regional market is driven by a high rate of chronic diseases, increasing willingness to adopt guideline-based care, and widespread use of evidence-based treatments for diabetes and CKD management. Regulatory support for SGLT2 inhibitors, as well as earlier adoption of cardiorenal treatment guidelines, is expected to further contribute to the SGLT2 inhibitors market Europe.
Asia Pacific
The Asia Pacific SGLT2 inhibitors market is expected to have the highest CAGR of 7.5% during the forecast period. The region has a large population, an aging population, rising diagnostic rates, and a growing prevalence of metabolic conditions. These are expected to drive long-term SGLT2 inhibitors market growth Asia Pacific in both developing and developed nations.
According to the SGLT2 inhibitors regional outlook, Asia is likely to contribute significantly to the global elderly population in the coming decades. With aging and urban lifestyles also leading to increased occurrences of diabetes and other associated lifestyle problems, long-term therapies for metabolism and renal functions are also likely to gain momentum.
The China and India SGLT2 inhibitor markets would remain important opportunities for the Asia Pacific region. The regions are expected to benefit from large populations with diabetes, expanding healthcare access, and the increasing use of branded and combination therapies.
Latin America and Middle East & Africa
Long-term growth prospects are foreseen for the Latin America SGLT2 inhibitors market and the Middle East & Africa, driven by increasing prevalence rates, improved diagnostic rates, and expanding healthcare infrastructures. Market penetration would differ across countries depending on their reimbursement systems, the affordability of branded formulations, and the availability of specialist care.
Competitive Landscape and Key Market Players
Market leaders are investing in research, label expansion, and commercialization strategies to solidify their position in the SGLT2 inhibitors competitive landscape. Partnerships, new product launches, fixed-dose combinations, and regional expansions are other strategies adopted by key players in SGLT2 inhibitors market.
Our SGLT2 inhibitor company analysis indicates that the market is influenced by a number of factors that determine the competition. Such factors involve the indication scope, familiarity, regulatory support, pricing, distribution reach, and lifecycle management. Products with stronger clinical support for cardiorenal indications and greater familiarity among physicians will continue to hold a competitive advantage, especially in a mature pharmaceutical market.
Major players in the market include AstraZeneca; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Eli Lilly and Company; Glenmark Pharmaceuticals Ltd.; Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.); Lexicon Pharmaceuticals, Inc.; Merck & Co., Inc.; Sanofi; and TheracosBio, LLC.
Boehringer Ingelheim has operations in both human pharmaceuticals and animal health. The company has a strong presence in the area of metabolism, cardiovascular diseases, and related diseases of the kidneys. Boehringer’s continuous growth in Jardiance reinforces its competitive positioning in the SGLT2 inhibitors market.
Glenmark Pharmaceuticals Limited specializes in pharmaceutical product development, manufacturing, and marketing. The firm operates in India, North America, Latin America, Europe, Japan, and other countries. The firm is enhancing its Glenmark diabetes portfolio through branded products.
List of Key Companies
- AstraZeneca
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Glenmark Pharmaceuticals Ltd.
- Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.)
- Lexicon Pharmaceuticals, Inc.
- Merck & Co., Inc.
- Sanofi
- TheracosBio, LLC
Industry Developments
- March 2025: Glenmark Pharmaceuticals introduced empagliflozin, a widely recognized SGLT2 inhibitor, into the Indian market under the brand name Glempa (10/25 mg). The rollout also featured its fixed-dose combinations: Glempa-L (combined with linagliptin) and Glempa-M (combined with metformin). This strategic move reinforced Glenmark’s diabetes portfolio. It also improved its competitive standing within India’s expanding anti-diabetes market.
- June 2024: AstraZeneca’s drug Farxiga (dapagliflozin) received FDA approval. The drug is meant to enhance glycaemic control in pediatric patients aged 10 years and older with type-2 diabetes (T2D).
- April 2024: Boehringer Ingelheim International GmbH reported its EMPACT-MI phase 3 clinical trial demonstrated a 10% decrease in the risk of hospitalization for heart failure in patients following the administration of Jardiance (empagliflozin).
Market Segmentation
By Indication Outlook (Revenue, USD Billion, 2021–2034)
- Cardiovascular
- Chronic Kidney Disease (CKD)
- Type 2 Diabetes
- Others
By Drug Outlook (Revenue, USD Billion, 2021–2034)
- Farxiga (Dapagliflozin)
- Inpefa (Sotagliflozin)
- Invokana (Canagliflozin)
- Jardiance (Empagliflozin)
- Qtern (Dapagliflozin/Saxagliptin)
- Other SGLT2 Inhibitors
By Distribution Channel Outlook (Revenue, USD Billion, 2021–2034)
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
By Regional Outlook (Revenue, USD Billion, 2021–2034)
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Vietnam
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
SGLT2 Inhibitors Market Report Scope
| Report Attributes | Details |
| Market Size in 2025 | USD 18.32 billion |
| Market Size in 2026 | USD 19.57 billion |
| Revenue Forecast by 2034 | USD 33.51 billion |
| CAGR | 6.9% |
| Base Year | 2025 |
| Historical Data | 2021–2024 |
| Forecast Period | 2026–2034 |
| Quantitative Units | Revenue in USD billion, and CAGR from 2026 to 2034 |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
|
| Regional Scope |
|
| Competitive Landscape | SGLT2 Inhibitors Industry Trend Analysis (2025) Company profiles/industry participants profiling include company overview, financial information, product/service benchmarking, and recent developments |
| Report Format | PDF + Excel |
| Customization | Report customization as per your requirements with respect to countries, regions, and segmentation. |
FAQ's
The global SGLT2 inhibitors market was valued at USD 18.32 billion in 2025 and is projected to reach USD 33.51 billion by 2034.
The market is projected to grow at a CAGR of 6.9% from 2026 to 2034.
North America held the largest market share in 2025 due to high diabetes prevalence and wider treatment access.
Asia Pacific is expected to register the fastest growth due to its large patient population and rising diagnosis rates.
SGLT2 inhibitors are increasingly important in CKD because they help reduce the risk of kidney disease progression in eligible patients.
The type 2 diabetes segment accounted for the largest share. This is due to the high prevalence of the diabetes form.
The online pharmacies segment is expected to grow the fastest over the forecast period, owing to the convenience offered by these pharmacies.
A few of the key players in the market include AstraZeneca; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Eli Lilly and Company; Glenmark Pharmaceuticals Ltd.; Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.); Lexicon Pharmaceuticals, Inc.; Merck & Co., Inc.; Sanofi; and TheracosBio, LLC.
The market is growing because of rising diabetes prevalence and increasing use in CKD and heart failure. It also benefits from expanded approvals and wider physician acceptance.
Major drugs include dapagliflozin, empagliflozin, canagliflozin, sotagliflozin, bexagliflozin, and selected combination products.
Download Sample Report of SGLT2 Inhibitors Market
Please fill out the form to request a customized copy of the research report.
